Identification of cytochrome P450 isoforms involved in citalopram N- demethylation by human liver microsomes

Journal of Pharmacology and Experimental Therapeutics

Volumn 280, Issue 2, 1997, Pages 927-933

  Kobayashi, Kaoru ^a   Chiba, Kan ^b   Yagi, Tomomi ^a   Shimada, Noriaki ^d   Taniguchi, Tomoyoshi ^e   Horie, Toru ^e   Tani, Masayoshi ^c   Yamamoto, Toshinori ^a   Ishizaki, Takashi ^b   Kuroiwa, Yukio ^a  

^a SHOWA UNIVERSITY   (Japan)

^b Research Institute   (Japan)

^c NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^d DAIICHI PURE CHEMICALS CO LTD   (Japan)

^e EISAI CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; COMPLEMENTARY DNA; CYTOCHROME P450 ISOENZYME; KETOCONAZOLE; MEPHENYTOIN; N DEMETHYLASE; TRIAZOLAM;

ARTICLE; CATALYSIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; HYDROXYLATION; LIVER MICROSOME METABOLISM; PRIORITY JOURNAL;

ARYL HYDROCARBON HYDROXYLASES; CITALOPRAM; CYTOCHROME P-450 ENZYME SYSTEM; DNA, COMPLEMENTARY; ISOENZYMES; KINETICS; MICROSOMES, LIVER; MIXED FUNCTION OXYGENASES; RECOMBINANT PROTEINS; SUBSTRATE SPECIFICITY;

EID: 14444282584     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. ALVÁN, G., BECHTEL, P., ISELIUS, L. AND GUNDERT-REMY, U.: Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur. J. Clin. Pharmacol. 39: 533-537, 1990.
2. BACK, D. J. AND TJIA, J. F.: Comparative effects of the antimycotic drugs ketoconazole, fluconazole, itraconazole and terbinafine on the metabolism of cyclosporin by human liver microsomes. Br. J. Clin. Pharmacol. 32: 624-626, 1991.
3. BRØSEN, K.: Recent developments in hepatic drug oxidation: Implications for clinical pharmacokinetics. Clin. Pharmacokinet. 18: 220-239, 1990.
4. CHIBA, K., MANABE, K., KOBAYASHI, K., TAKAYAMA, Y., TANI, M. AND ISHIZAKI, T.: Development and preliminary application of a simple assay of S-mephenytoin 4-hydroxylase in human liver microsomes. Eur. J. Clin. Pharmacol. 44: 559-562, 1993.
5. CRESPI, C. L.: Xenobiotic-metabolizing human cells as tools for pharmacological and toxicological research. Adv. Drug Res. 26: 179-235, 1995.
6. DAHL, M.-L. AND BERTILSSON, L.: Genetically variable metabolism of antidepressants and neuroleptic drugs. Pharmacogenetics 3: 61-70, 1993.
7. DE MORAIS, S. M. F., WILKINSON, G. R., BLAISDELL, J., MEYER, U. A., NAKAMURA, K. AND GOLDSTEIN, J. A.: Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol. Pharmacol. 46: 594-598, 1994a.
8. DE MORAIS, S. M. F., WILKINSON, G. R., BLAISDELL, J., NAKAMURA, K., MEYER, U. A. AND GOLDSTEIN, J. A.: The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J. Biol. Chem. 269: 15419-15422, 1994b.
9. GOLDSTEIN, J. A., FALETTO, M. B., ROMKES-SPARKS, M., SULLIVAN, T., KITAREEWAN, S., RAUCY, J. L., LASKER, J. M. AND GHANAYEM, B. I.: Evidence that CYP2C19 is the major (S)-mephenytoin 4′-hydroxylase in humans. Biochemistry 33: 1743-1752, 1994.
10. GUENGERICH, F. P.: Oxidation of 17α-ethinylestradiol by human liver cytochrome P-450. Mol. Pharmacol. 33: 500-508, 1988.
11. GUENGERICH, F. P., MARTIN, M. V., BEAUNE, P. H., KREMERS, P., WOLFF, T. AND WAXMAN, D. J.: Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidation drug metabolism. J. Biol. Chem. 261: 5051-5060, 1986a.
12. GUENGERICH, F. P., MÜLLER-ENOCH, D. AND BLAIR, I. A.: Oxidation of quinidine by human liver cytochrome P-450. Mol. Pharmacol. 30: 287-295, 1986b.
13. HORAI, Y., NAKANO, M., ISHIZAKI, T., ISHIKAWA, K., ZHOU, H.-H., ZHOU, B.-J., LIAO, C.-L. AND ZHANG, L.-M.: Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese. Clin. Pharmacol. Ther. 46: 198-207, 1989.
14. HYTTEL, J.: Citalopram: Pharmacological profile of a specific serotonin uptake inhibitor with antidepressant activity. Prog. Neuropsychopharmacol. Biol. Psychiatry 6: 277-295, 1982.
15. JACQZ, M., DULAC, H. AND MATHIEU, H.: Phenotyping polymorphic drug metabolism in the French Caucasian population. Eur. J. Clin. Pharmacol. 35: 167-171, 1988.
16. KAMINSKY, L. S., FASCO, M. J. AND GUENGERICH, F. P.: Production and application of antibodies to rat liver cytochrome P-450. Methods Enzymol. 74: 262-272, 1981.
17. KOBAYASHI, K., YAMAMOTO, T., CHIBA, K., TANI, M., ISHIZAKI, T. AND KUROIWA, Y.: The effects of selective serotonin reuptake inhibitors and their metabolites on S-mephenytoin 4′-hydroxylase activity in human liver microsomes. Br. J. Clin. Pharmacol. 40: 481-485, 1995.
18. KRONBACH, T., MATHYS, D., UENO, M., GONZALEZ, F. J. AND MEYER, U. A.: Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol. Pharmacol. 36: 89-96, 1989.
19. KÜPFER, A. AND PREISIG, R.: Pharmacogenetics of mephenytoin: A new drug hydroxylation polymorphism in man. Eur. J. Clin. Pharmacol. 26: 753-759, 1984.
20. LOWRY, O. H., ROSEBROUGH, N. J., FARR, A. L. AND RANDALL, R. J.: Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193: 265-275, 1951.
21. OYEHAUG, E. AND OSTENSEN, E. T.: High-performance liquid Chromatographic determination of citalopram and four of its metabolites in plasma and urine samples from psychiatric patients. J. Chromatogr. Biomed. Appl. 308: 199-208, 1984.
22. ROCHAT, B., AMEY, M. AND BAUMANN, P.: Analysis of enantiomers of citalopram and its demethylated metabolites in plasma of depressive patients using chiral reverse-phase liquid chromatography. Ther. Drug Monit. 17: 273-279, 1995.
23. SHIMADA, T., MISONO, K. AND GUENGERICH, F. P.: Human liver microsomal cytochrome P-450 mephenytoin 4-hydroxylase, a prototype of genetic polymorphism in oxidative drug metabolism. J. Biol. Chem. 261: 909-921, 1986.
24. SINDRUP, S. H., BRØSEN, K., HANSEN, M. G. J., AAES-JØRGENSEN, T., OVERØ, K. F. AND GRAM, L. F.: Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms. Ther. Drug Monit. 15: 11-17, 1993.
25. SOHN, D.-R., KUSAKA, M., ISHIZAKI, T., SHIN, S.-G., JANG, I.-J., SHIN, J.-G. AND CHIBA, K.: Incidence of S-mephenytoin hydroxylation deficiency in a Korean population and the interphenotypic differences in diazepam pharmacokinetics. Clin. Pharmacol. Ther. 52: 160-169, 1992.
26. SPINA, E. AND CAPRITI, A.: Pharmacogenetic aspects in the metabolism of psychotropic drugs: Pharmacokinetic and clinical implications. Pharmacol. Res. 29: 121-137, 1994.
27. WEDLUND, P. J., ASLANIAN, W. S., JACQZ, E., McALLISTER, C. B., BRANCH, R. A. AND WILKINSON, G. R.: Phenotypic differences in mephenytoin pharmacokinetics in normal subjects. J. Pharmacol. Exp. Ther. 234: 662-669, 1985.
28. WEDLUND, P. J., ASLANIAN, W. S., McALLISTER, C. B., WILKINSON, G. R. AND BRANCH, R. A.: Mephenytoin hydroxylation deficiency in Caucasians: Frequency of a new oxidative drug metabolism polymorphism. Clin. Pharmacol. Ther. 36: 773-780, 1984.
29. WILKINSON, G. R., GUENGERICH, F. P. AND BRANCH, R. A.: Genetic polymorphism of S-mephenytoin hydroxylation. Pharmacol. Ther. 43: 53-76, 1989.
30. WRIGHTON, S. A. AND RING, B. J.: Inhibition of human CYP3A catalyzed 1′-hydroxy midazolam formation by ketoconazole, nifedipine, erythromycin, cimetidine, and nizatidine. Pharm. Res. 11: 921-924, 1994.
31. WRIGHTON, S. A., STEVENS, J. C., BECKER, G. W. AND VANDENBRANDEN, M.; Isolation and characterization of human liver cytochrome P4502C19: Correlation between 2C19 and S-mephenytoin 4′-hydroxylation. Arch. Biochem. Biophys. 306: 240-245, 1993.
32. YASUMORI, T., MURAYAMA, N., YAMAZOE, Y. AND KATO, R.: Polymorphism in hydroxylation of mephenytoin and hexobarbital stereoisomers in relation to hepatic P-450 human-2. Clin. Pharmacol. Ther. 47: 313-322, 1990.